Research Areas
In ths section, by far, most Axon Ligands™ are categorized as research tools that find their application in cell signaling and oncology. Targeting a multitude of specific enzymes and receptors, they either stimulate or block particular cellular signaling pathways that are implicated in various kinds of cancer. Naturally, all products in this section can also be found by their specific biological targets as listed in the sections of enzymes, receptors, transcription factors, proteins and/or signaling pathways. Besides the comprehensive set of compounds that targe cell signaling and oncology, selections of Axon Ligands™ have also been made for other research area's such as cardiovascular diseases, angiogenisis, epigenetics, stem cell research, among many others.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2861 | ZK 756326 dihydrochloride | CCR8 agonist | €90.00 | |
| 2636 | YJC-10592 | CCR2 antagonist | €145.00 | |
| 1620 | WZ 811 | CXCR4 antagonist | €80.00 | |
| 2685 | Vercirnon | CCR9 antagonist | €135.00 | |
| 2993 | UNBS5162 | Pan-antagonist of CXCL chemokine expression | €95.00 | |
| 2593 | SB 332235 | Nonpeptide CXCR2 antagonist exhibiting significant anti-inflammatory effects | €105.00 | |
| 1559 | SB 265610 | CXCR2 antagonist | €95.00 | |
| 2921 | LIT-927 | Selective, locally and orally active CXCL12 neutraligand | €95.00 | |
| 1800 | CXCR3 Antagonist 6c | CXCR3 antagonist | €135.00 | |
| 2665 | Cenicriviroc | Oral CCR5-antagonist for treatment of HIV infection | €145.00 | |
| 2082 | BX 471 | Selective CCR1 receptor antagonist | €105.00 | |
| 2255 | AZD 8797 | Potent and selective antagonist of the Fractalkine receptor (FKN or CX3CR1) | €120.00 | |
| 2842 | AZD 2098 | Potent, selective and bioavailable CCR4 receptor antagonist | €125.00 | |
| 1930 | AMD 3465 hexahydrobromide | Potent and selective CXCR4 antagonist | €85.00 | |
| 1738 | AMD 3100 | CXCR4 antagonist | €85.00 | |